Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab The Irish National Adverse Event Study 2 (INAES 2): longitudinal trends in adverse event rates in the Irish healthcare system BMJ Quality & Safety Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database Scientific Reports Population Scale Identification of Differential Adverse Events Before and During a Pandemic Zitnik Lab